

Jemperli and Opdualag™ to have site-of-care requirements for BCN commercial members starting July 1

For dates of service on or after July 1, 2023, we're adding site-of-care requirements for Blue Care Network group and individual commercial members for the following drugs covered under the medical benefit:

- Jemperli (dostarlimab-gxly), HCPCS code J9272
- Opdualag (nivolumab and relatlimab-rmbw), HCPCS code J9298

When you submit prior authorization requests for these drugs to Carelon Medical Benefits Management (former known as AIM Specialty Health®), the [ProviderPortal](#)®* will prompt you to select a site of care. The request will be approved automatically if it meets clinical criteria for the drug and is for one of the following sites of care:

- Doctor's or other health care provider's office
- Ambulatory infusion center
- The member's home, when the medication is administered by a home infusion therapy provider

Additional information or documentation may be required for requests to administer Jemperli and Opdualag in an outpatient hospital setting.

As a reminder, these drugs already require prior authorization; providers can submit prior authorization requests to Carelon. The new site-of-care requirements are in addition to the current prior authorization requirements.

For members who start courses of treatment with Jemperli and Opdualag in an outpatient hospital setting before July 1, 2023:

- Those members will be able to continue receiving the drug in an outpatient hospital setting through Jan. 1, 2024.
- After Jan. 1, 2024, those members will need to request prior authorization again and the site-of-care requirements outlined above will apply.

Note: The site-of-care requirements don't apply to Blue Cross Blue Shield of Michigan commercial members.

List of requirements

For additional information on requirements related to drugs covered under the medical benefit, refer to the following Blue Cross commercial and BCN commercial drug lists:



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Provider alert

BCN commercial

Categories: Authorizations/referrals, Pharmacy

Date posted: March 16, 2023

- [Medical oncology prior authorization list for Blue Cross commercial fully insured and BCN commercial members](#)
- [Blue Cross and BCN utilization management medical drug list](#)

We'll update the pertinent drug lists to reflect the information in this message prior to the effective date.

Authorization isn't a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.

*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.

Carelon Medical Benefits Management (formerly known as AIM Specialty Health) is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage authorizations for select services.